ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded down 17.8% on Thursday . The company traded as low as GBX 3.70 and last traded at GBX 3.70. Approximately 1,186,007 shares changed hands during trading, a decline of 55% from the average session volume of 2,650,268 shares. The stock had previously closed at GBX 4.50.
ImmuPharma Stock Performance
The company has a market capitalization of £23.08 million, a PE ratio of -10.00 and a beta of 3.02. The company’s 50-day simple moving average is GBX 4.21 and its 200-day simple moving average is GBX 5.30.
ImmuPharma (LON:IMM – Get Free Report) last announced its earnings results on Wednesday, May 27th. The company reported GBX (0.37) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 353.21%. Analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
- Tesla: After a Rough Quarter, 2 Very Different Futures Come Into Focus
- Why NXP Semiconductors Could Be the AI Stock Everyone Is Missing
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
